Tamekia Smith, ARNP-C Preventive Medicine - Undersea and Hyperbaric Medicine Medicare: Accepting Medicare Assignments Practice Location: 305 Memorial Medical Pkwy Ste 101, Daytona Beach, FL 32117 Phone: 386-231-3615 |
Dr. Omayra M. Quijano-vega, MD Preventive Medicine - Undersea and Hyperbaric Medicine Medicare: Medicare Enrolled Practice Location: 1667 North Clyde Morris Blvd, Suite 2, Daytona Beach, FL 32117 Phone: 434-248-7508 |
News Archive
Disease-modifying drugs (DMDs) are injected medications used to slow the progression of multiple sclerosis, and have been shown to reduce the frequency and severity of relapses. But according to a new study led by St. Michael's Hospital and the Institute for Clinical Evaluative Sciences, adherence to all DMDs is low, with less than half of patients, or 44 per cent, continually adherent after two years.
Scientists have identified a protein that acts as a "master switch" in certain white blood cells, determining whether they promote or inhibit inflammation. The study, published in the journal Nature Immunology, could help researchers look for new treatments for diseases such as rheumatoid arthritis that involve excessive inflammation.
Epigem, a high-tech British micro engineering company, is supporting research into Multiple Sclerosis (MS) with a new PhD programme to create a novel drug screening platform. This will accelerate the production of MS models and pre-clinical drug development, in order to understand better the disease process and its periods of remission.
Cardiovascular disease is one of the biggest contributors to the global burden of disease, and by 2020 will be the number one contributor according to figures from the World Health Organisation. In response, the International Centre for Circulatory Health (ICCH) has been set up by Imperial College London and St Mary's NHS Trust as an international research centre to develop new treatments and preventative strategies for cardiovascular disease around the world.
Avila Therapeutics™, Inc., a biotechnology company developing novel covalent drugs that treat diseases through protein silencing, presented results of preclinical studies on its highly selective, small molecule Hepatitis C Virus (HCV) protease inhibitor, AVL-181. Avila showed that AVL-181 promoted complete viral clearance in vitro when used at clinically-relevant concentrations in combination with other HCV therapies.
› Verified 7 days ago